Evidence map›Paper›PMID 30827726›Full record

ArticleGynecologic oncology2019

GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study.

Rebecca A Brooks, David S Tritchler, Kathleen M Darcy, Heather A Lankes, Ritu Salani, Paul Sperduto, Saketh Guntupalli, Paul DiSilvestro, Joshua Kesterson, Alexander B Olawaiye and 10 more

Open access · greenAbstract read
In one paragraph

Article in Gynecologic oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. [Association between HULC gene locus rs7763881 polymorphism and recurrence and metastasis after radical resection in hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
    Article
  4. Article
  5. Improving response to progestin treatment of low-grade endometrial cancer.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2020
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 17 institutions in 2 countries.

Rebecca A BrooksDivision of Gynecologic Oncology, University of California at Dabvis, Sacramento, CA, United States of America. Electronic address: rebrooks@ucdavis.edu.
David S TritchlerSchool of Public Health, University of Toronto, Toronto, ON, Canada.
Kathleen M DarcyGynecologic Cancer Center of Excellence, Department of Obstetrics and Gynecology, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America; Department of Obstetrics and Gynecology, Virginia Commonwealth University School of Medicine, Inova Medical Campus, Falls Church, VA, United States of America.
Heather A LankesBiopathology Center, The Research Institute at Nationwide Children's Hospital, Columbus, OH, United States of America; Division of Gynecologic Oncology, The Ohio State University, Columbus, OH, United States of America.
Ritu SalaniDivision of Gynecologic Oncology, The Ohio State University, Columbus, OH, United States of America.
Paul SperdutoDivision of Radiation Oncology, Ridgeview Medical Center, Waconia, MN, United States of America.
Saketh GuntupalliDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Denver, CO, United States of America.
Paul DiSilvestroDepartment of Obstetrics and Gynecology, Program in Women's Oncology, Women & Infants Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, United States of America.
Joshua KestersonDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Penn State College of Medicine, Milton S. Hershey Medical Center, United States of America.
Alexander B OlawaiyeDepartment of Obstetrics, Gynecology, and Reproductive Services, University of Pittsburgh Medical Center, Magee-Women's Hospital, Pittsburgh, PA, United States of America.
Katherine MoxleyDepartment of OB/GYN, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States of America.
Steven WaggonerDepartment of Obstetrics and Gynecology, Case Western Reserve University, Cleveland, OH, United States of America.
Alessandro SantinDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, United States of America.
Janet S RaderDepartment of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, United States of America.
Nora T KizerDepartment of Obstetrics and Gynecology, Springfield Clinic, Springfield, IL, United States of America.
Premal H ThakerDivision of Gynecologic Oncology and Siteman Cancer Center, Washington University, St Louis, MO, United States of America.
Matthew A PowellDivision of Gynecologic Oncology and Siteman Cancer Center, Washington University, St Louis, MO, United States of America.
David G MutchDivision of Gynecologic Oncology and Siteman Cancer Center, Washington University, St Louis, MO, United States of America.
Michael J BirrerDivision of Hematology Oncology, The University of Alabama, Birmingham, AL, United States of America.
Paul J GoodfellowDivision of Gynecologic Oncology, The Ohio State University, Columbus, OH, United States of America.
Washington University in St. Louis · USThe Ohio State University · USBrown University · USCase Western Reserve University · USMagee-Womens Hospital · USMedical College of Wisconsin · USNationwide Children's Hospital · USPenn State Milton S. Hershey Medical Center · USRidgeview Medical Center · USSpringfield Clinic · USUniformed Services University of the Health Sciences · USUniversity of Alabama at Birmingham · USUniversity of California System · USUniversity of Colorado Denver · USUniversity of Oklahoma Health Sciences Center · USUniversity of Toronto · CAYale University · US

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam · 2014 to 2026
$146.4M
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NRG Oncology Biospecimen BankU24CA196067 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Tanner J. Freeman, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$42.6M
A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical TrialsUG1CA233193 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Muhammad Furqan · 2019 to 2026
$13.7M
WASHINGTON UNIVERSITY / SITEMAN CANCER CENTER LEAD ACADEMIC SITEUG1CA233339 · NCI · WASHINGTON UNIVERSITY · PI NANCY L BARTLETT, Clifford Grant Robinson · 2019 to 2026
$11.3M
OSU as a Network Lead Academic Participating Site for the NCI NCTNUG1CA233331 · NCI · OHIO STATE UNIVERSITY · PI John L. Hays, Dwight H. Owen · 2019 to 2026
$8.9M
Washington University/ Siteman Cancer Center Lead Academic SiteU10CA180833 · NCI · WASHINGTON UNIVERSITY · PI BARTLETT, NANCY L, KOZOWER, BENJAMIN D · 2014 to 2018
$7.6M
NCI National Clinical Trials Network - Lead Academic Participating SiteUG1CA233324 · NCI · UNIVERSITY OF COLORADO DENVER · PI ANTHONY D ELIAS · 2019 to 2026
$5.2M
DEFECTIVE DNA MISMATCH REPAIR IN ENDOMETRIAL CANCERSR01CA071754 · NCI · WASHINGTON UNIVERSITY · PI GOODFELLOW, PAUL JOSEPH · 1997 to 2009
$2.6M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA071754NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180833NCI NIH HHS U10 CA180868NCI NIH HHS U24 CA196067NCI NIH HHS UG1 CA233193NCI NIH HHS UG1 CA233324NCI NIH HHS UG1 CA233331NCI NIH HHS UG1 CA233339
6 · The paper itself

Abstract

objectivesThe ability to stratify a patient's risk of metastasis and survival permits more refined care. A proof of principle study was undertaken to investigate the relationship between single nucleotide polymorphisms (SNPs) in literature based candidate cancer genes and the risk of nodal metastasis and clinical outcome in endometrioid endometrial cancer (EEC) patients.

methodsSurgically-staged EEC patients from the Gynecologic Oncology Group or Washington University School of Medicine with germline DNA available were eligible. Fifty-four genes represented by 384 SNPs, were evaluated by Illumina Custom GoldenGate array. Association with lymph node metastases was the primary outcome. Progression-free survival (PFS) and overall survival (OS) was also evaluated.

results361 SNPs with high quality genotype data were evaluated in 337 patients with outcome data. Five SNPs in CXCR2 had an odds ratio (OR) between 0.68 and 0.70 (p-value ≤ 0.025). The A allele rs946486 in ABL had an OR of 1.5 (p-value = 0.01) for metastasis. The G allele in rs7795743 in EGFR had an OR for metastasis of 0.68 (p-value = 0.02) and hazard ratio (HR) for progression of 0.66 (p-value = 0.004). Importantly, no SNP met genome wide significance after adjusting for multiple test correcting and clinical covariates. The A allele in rs2159359 SNP in NME1 and the G allele in rs13222385 in EGFR were associated with worse OS. Both exhibited genome wide significance; rs13222385 remained significant after adjusting for prognostic clinical variables.

conclusionSNPs in cancer genes including rs2159359 SNP in NME1 and rs13222385 in EGFR may stratify risk in EEC and are prioritized for further investigation.

Indexed as

AgedBiomarkers, TumorCase-Control StudiesDisease ProgressionEndometrial NeoplasmsEndometriumErbB ReceptorsFemaleHumansLymphatic MetastasisMiddle AgedNeoplasm StagingNM23 Nucleoside Diphosphate KinasesPolymorphism, Single NucleotidePrognosisProgression-Free SurvivalBiomarkers, TumorEGFR protein, humanErbB ReceptorsNM23 Nucleoside Diphosphate KinasesNME1 protein, humanEndometrial cancerNode positivityRisk stratificationSNP association

Identifiers

PMID30827726
PMCPMC6486855
OpenAlexW2919621058

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.